TSHA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Taysha Gene Therapies Inc (TSHA) is not a strong buy for a beginner, long-term investor at this time. The stock shows limited positive momentum, regulatory uncertainty in the biotech sector, and weak financial performance. While hedge funds are increasing their positions and analysts have a favorable outlook, the lack of significant positive catalysts and weak technical indicators suggest holding off on investment for now.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 42.703, with no clear signal. Moving averages are converging, suggesting indecision in price direction. The stock is trading near support levels (S1: 4.395), with resistance at R1: 4.956. Overall, technical indicators do not suggest a strong buy opportunity.
Hedge funds have significantly increased their buying activity by 649.63% over the last quarter. Analysts have raised the price target to $11 from $8, citing optimism around the company's pivotal Rett syndrome study and alignment with the FDA.
Regulatory uncertainty in the biotech sector, with the FDA rejecting or delaying multiple gene therapy applications, has created investor concerns. Recent financial performance shows a 100% drop in revenue and a YoY increase in net loss. The stock's recent trend suggests a likelihood of minor declines in the short term.
In 2025/Q3, revenue dropped to $0 (-100% YoY), net income improved to -$32.73M (+28.24% YoY), and EPS declined to -0.09 (-10% YoY). Gross margin remained at 100%, but the absence of revenue is a significant concern.
Wells Fargo analyst Zachary Fadem raised the price target to $11 from $8 and maintains an Overweight rating, citing optimism around the company's Rett syndrome study and favorable FDA alignment. Analysts expect continued outperformance for the stock.
